← Leaderboards
Hiroaki Serizawa
Neovascularx, Inc
$305,321
Attributed
$305,321
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$305,321 · 1
By mechanism
R43$305,321 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Anti-Bacterial Agents”
- Paul Sebahar · Curza Inc$2,858,436
- Zheng Yan · University Of Missouri-Columbia$2,588,415
- Ryan Bock · Sintx Technologies, Inc.$2,548,555
- Vidmantas Petraitis · Hackensack University Medical Center$2,359,697
- Brian Kane · Spero Therapeutics, Inc.$2,105,800
- Tsuyoshi Uehara · Venatorx Pharmaceuticals, Inc.$2,000,000
Research focus
Anti-Bacterial AgentsAntibioticsApoptosisAtrophicBackBlindnessChemistryChoroidal NeovascularizationCicatrixClinical TrialsCommercializationDesignDevelopment PlansDiagnosisDoseDrug DevelopmentDrug ResistanceDrug TargetingElderlyExudative Age-Related Macular DegenerationEyedropsFda ApprovedFeedbackAnatomy